T2 Biosystems, INC Form 4 insider transactions

Seymour Liebman, a director at T2 Biosystems, was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments.

T2 Biosystems' Chief Commercial Officer, Brett A. Giffin, was granted 360,000 restricted stock units (RSUs) on November 4, 2024, which vest over time.

Director Laura Lee Adams was granted 25,000 restricted stock units (RSUs) in T2 Biosystems, which will vest in two equal annual installments starting November 4, 2025.

Director John Cumming of T2 Biosystems was granted 35,000 restricted stock units that vest in two equal annual installments.

T2 Biosystems' General Counsel, Michael Terrence Gibbs, was granted 380,000 restricted stock units (RSUs) on November 4, 2024, which vest over different periods.

A T2 Biosystems director, Ninfa Saunders, was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments starting November 4, 2025.

Director Robin Toft of T2 Biosystems was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments starting November 4, 2025.

T2 Biosystems CEO, John J. Sperzel III, was granted 980,000 restricted stock units (RSUs) in two tranches, contingent on shareholder approval of an amended incentive plan.

T2 Biosystems director David B. Elsbree was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments starting November 4, 2025.

T2 Biosystems' CFO, John M. Sprague, was granted 360,000 restricted stock units (RSUs) in two tranches, contingent on shareholder approval of an amended incentive plan.

Director David B. Elsbree of T2 Biosystems sold 55 shares of common stock on September 13, 2024.

CR Group L.P. reports the conversion of Series A and Series B Preferred Stock into common stock of T2 Biosystems, Inc.

CR Group L.P. and affiliated entities acquired shares of T2 Biosystems common stock by converting outstanding debt, as reported in a recent SEC filing.

CR Group L.P. and affiliated entities acquired additional shares of T2 Biosystems common stock and Series A Convertible Preferred Stock through the conversion of outstanding debt, as detailed in a recent SEC filing.

John J. Sperzel III, a director and officer of T2 Biosystems, Inc., executed restricted stock units (RSUs) on February 24, 2024, acquiring 67 shares of common stock.

Chief Financial Officer John M. Sprague of T2 Biosystems, Inc. reports a transaction involving restricted stock units on February 24, 2024.

Michael Terrence Gibbs, General Counsel of T2 Biosystems, acquired 29 shares of common stock on February 24, 2024, through the vesting of restricted stock units.